Fifty years ago, the U.S. Supreme Court ruled that a patent license agreement that requires the licensee to pay
royalties after the expiration of the licensed patent is unlawful per se, because such payments effectively extend the patent monopoly beyond the statutory term and prevent the invention from becoming part...
Furthermore, the «Queen» patent
royalties may continue longer than one might initially anticipate; a chart prepared for investors in the March 8 presentation shows
royalties continuing for up to 30 months
after patent
expiration because
royalty payments must be made on medicines produced during the patent lifetime, not just sold during this period.